LUHUA WANG to Time Factors
This is a "connection" page, showing publications LUHUA WANG has written about Time Factors.
Connection Strength
0.294
-
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019 11; 33(11):2762-2766.
Score: 0.064
-
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179.
Score: 0.047
-
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41.
Score: 0.044
-
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol. 2012 Dec; 35(6):562-5.
Score: 0.040
-
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology. 2010 Apr; 15(2):70-3.
Score: 0.033
-
CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010 Mar; 45(3):498-504.
Score: 0.032
-
Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014 Aug; 49(8):1036-41.
Score: 0.011
-
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70.
Score: 0.010
-
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7.
Score: 0.008
-
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
Score: 0.007